Drug-discovery AI agents are built for small-molecule, big-pharma settings and lack peptide, in vivo, training-loop, small-lab, and multi-objective capabilities, even though LLMs themselves can reason about peptides.
hub
KEGG for taxonomy-based analysis of pathways and genomes.Nucleic Acids Research, 51(D1):D587–D592, 2023
1 Pith paper cite this work, alongside 6,466 external citations. Polarity classification is still indexing.
1
Pith paper citing it
6,466
external citations · OpenAlex
hub tools
fields
q-bio.QM 1years
2026 1verdicts
CONDITIONAL 1representative citing papers
citing papers explorer
-
Beyond SMILES: Evaluating Agentic Systems for Drug Discovery
Drug-discovery AI agents are built for small-molecule, big-pharma settings and lack peptide, in vivo, training-loop, small-lab, and multi-objective capabilities, even though LLMs themselves can reason about peptides.